Get started
Author

Debjani Grenier

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
2017 · Miguel Martin, Frankie A Holmes, et al. · The Lancet Oncology · 587
Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
2009 · Hyman B. Muss, Donald A. Berry, et al. · New England Journal of Medicine · 555
PDF
The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy
2011 · Nazanin Fallah-Rad, Jonathan R. Walker, et al. · Journal of the American College of Cardiology · 484
PDF
Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study
2008 · Deepa Wadhwa, Nazanin Fallah-Rad, et al. · Breast Cancer Research and Treatment · 155
Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104
2010 · Ann H. Partridge, Laura Archer, et al. · Journal of Clinical Oncology · 128
PDF
Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories
2004 · Karen A. Gelmon, John Mackey, et al. · Clinical Breast Cancer · 126
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial
2019 · Hyman B. Muss, Mei-Yin C. Polley, et al. · Journal of Clinical Oncology · 79
PDF
Bone mineral density and risk of postmenopausal breast cancer
2010 · Debjani Grenier, Andrew L. Cooke, et al. · Breast Cancer Research and Treatment · 34
Promoting consultation recording practice in oncology: identification of critical implementation factors and determination of patient benefit
2012 · Thomas F. Hack, J. Dean Ruether, et al. · Psycho-Oncology · 33
A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles
2022 · Sonal Gandhi, Muriel Brackstone, et al. · Breast Cancer Research and Treatment · 23
PDF
Neoadjuvant Therapy for Breast Cancer: Updates and Proceedings From the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer
2018 · A. Arnaout, J. Lee, et al. · Current Oncology · 23
PDF
Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials
2016 · Jeffrey Graham, Marshall Pitz, et al. · Cancer Treatment Reviews · 23
Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake
2020 · Julian O. Kim, Daniel J. Schaid, et al. · Cancer Prevention Research · 20
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus
2021 · Thiago P. Muniz, Daniel V. Araujo, et al. · Cancers · 14
PDF
Ten ways to get a grip on designing and implementing a competency-based medical education training program
2021 · Tina Hsu, Flavia De Angelis, et al. · Canadian Medical Education Journal · 13
PDF
Study protocol: Addressing evidence and context to facilitate transfer and uptake of consultation recording use in oncology: A knowledge translation implementation study
2011 · Thomas F Hack, J Dean Ruether, et al. · Implementation Science · 10
PDF
PD-1 Inhibition in Malignant Melanoma and Lack of Clinical Response in Chronic Lymphocytic Leukemia in the Same Patients: A Case Series
2020 · I. Landego, D. Hewitt, et al. · Current Oncology · 8
PDF
CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907
2008 · A. H. Partridge, L. E. Archer, et al. · Journal of Clinical Oncology · 6
Impact of a breast cancer (BC) polygenic risk score (PRS) on the decision to take preventive endocrine therapy (ET): The Genetic Risk Estimate (GENRE) trial.
2019 · Julian Oliver Kim, Daniel J. Schaid, et al. · Journal of Clinical Oncology · 4
Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED).
2021 · Thiago Pimentel Muniz, Daniel Vilarim Araujo, et al. · Journal of Clinical Oncology · 2
Abstract P5-14-02: Clinical predictors of benefit from fulvestrant in advanced breast cancer: A meta-analysis of randomized controlled trials
2016 · S Niraula, M Pitz, et al. · Cancer Research · 1
Metastatic Breast Cancer in a Patient with Fanconi Anemia
2014 · Jeffrey Graham, Debjani Grenier, et al. · Blood · 1
Can flaxseed “milk” prevent anthracycline mediated cardiotoxicity in women with breast cancer (CANFLAX-BC)?
2026 · Vibhuti Arya, Lana Mackic, et al. · Cardio-Oncology
Can flax "milk" prevent chemotherapy mediated cardiotoxicity in women with breast cancer?
2025 · D Jassal, V Arya, et al. · European Heart Journal - Cardiovascular Imaging
Supplementary Data from Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake
2023 · Julian O. Kim, Daniel J. Schaid, et al.
Works count: 38
Citation count: 2,327
H-index: 14
I10-index: 16
Year
Topic
Type